The relationship between microbes living inside tumors and cancer biology has been one of the most contested frontiers in oncology over the past decade. Settling that debate matters enormously: if genuine microbial colonization drives tumor evolution or shapes treatment response, it opens entirely new therapeutic targets. This large-scale analysis provides the most rigorous accounting yet of what microbes actually inhabit human tumors versus what is contamination artifact.
Drawing on 16,369 high-depth tumor whole-genome sequences from the UK 100,000 Genomes Project, researchers built a purpose-designed host-subtraction pipeline and applied strict decontamination thresholds. The striking finding was a null result for most cancer types — microbial signals were statistically indistinguishable from background noise. The exception was orodigestive cancers, where genuine multi-kingdom polymicrobial communities were identified comprising bacteria, fungi, archaea, viruses, and even Trichomonas, a protozoan parasite. Critically, tumors harboring microsatellite instability or mutations in the proofreading polymerases POLE and POLD1 showed significantly elevated microbial colonization, with microbial load correlating with overall tumor mutation burden.
This work carries several important implications. First, it delivers a methodological corrective to years of over-claimed pan-cancer microbiome findings — much of the previously reported signal was almost certainly contamination. Second, the POLE/POLD1 and microsatellite-instability link is biologically provocative: these hypermutator phenotypes may create permissive niches for microbial colonization, or alternatively, microbial presence may contribute to mutagenic stress in an underappreciated feedback loop. Third, confining genuine tumor microbiomes to the orodigestive tract aligns with anatomical plausibility — these sites maintain direct oral and gut microbial exposure. For longevity-oriented readers, the takeaway is nuanced: the gut-oral microbiome axis remains a legitimate cancer-biology target, but systemic tumor microbiome claims should be treated skeptically until validated with equivalent methodological rigor. This is a potentially paradigm-correcting, not merely paradigm-shifting, study.